Angiogenesis inhibitor

DRUG CLASS:

Angiogenesis inhibitor

News alerts, weekly reports and conference planners

Related drugs:

No biomarker	Glioblastoma	No biomarker	Glioblastoma	VB-111 Sensitive: B - Late Trials VB-111 Sensitive : B	VB-111 Sensitive: B - Late Trials VB-111 Sensitive : B
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	VB-111 Sensitive: B - Late Trials VB-111 Sensitive : B	VB-111 Sensitive: B - Late Trials VB-111 Sensitive : B
EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer	EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer	SIBP-04 (bevacizumab biosimilar) Sensitive: B - Late Trials SIBP-04 (bevacizumab biosimilar) Sensitive : B	SIBP-04 (bevacizumab biosimilar) Sensitive: B - Late Trials SIBP-04 (bevacizumab biosimilar) Sensitive : B
BRAF V600E	Colorectal Cancer	BRAF V600E	Colorectal Cancer	Angiogenesis inhibitor Sensitive: C3 – Early Trials Angiogenesis inhibitor Sensitive : C3	Angiogenesis inhibitor Sensitive: C3 – Early Trials Angiogenesis inhibitor Sensitive : C3
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	PD1 inhibitor + Angiogenesis inhibitor Sensitive: C3 – Early Trials PD1 inhibitor + Angiogenesis inhibitor Sensitive : C3	PD1 inhibitor + Angiogenesis inhibitor Sensitive: C3 – Early Trials PD1 inhibitor + Angiogenesis inhibitor Sensitive : C3
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	EGFR inhibitor + Angiogenesis inhibitor Sensitive: C3 – Early Trials EGFR inhibitor + Angiogenesis inhibitor Sensitive : C3	EGFR inhibitor + Angiogenesis inhibitor Sensitive: C3 – Early Trials EGFR inhibitor + Angiogenesis inhibitor Sensitive : C3
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	Angiogenesis inhibitor Sensitive: C3 – Early Trials Angiogenesis inhibitor Sensitive : C3	Angiogenesis inhibitor Sensitive: C3 – Early Trials Angiogenesis inhibitor Sensitive : C3
TP53 mutation	Hepatocellular Cancer	TP53 mutation	Hepatocellular Cancer	PD1 inhibitor + Angiogenesis inhibitor Resistant: C3 – Early Trials PD1 inhibitor + Angiogenesis inhibitor Resistant : C3	PD1 inhibitor + Angiogenesis inhibitor Resistant: C3 – Early Trials PD1 inhibitor + Angiogenesis inhibitor Resistant : C3
ARID1A mutation	Hepatocellular Cancer	ARID1A mutation	Hepatocellular Cancer	PD1 inhibitor + Angiogenesis inhibitor Resistant: C3 – Early Trials PD1 inhibitor + Angiogenesis inhibitor Resistant : C3	PD1 inhibitor + Angiogenesis inhibitor Resistant: C3 – Early Trials PD1 inhibitor + Angiogenesis inhibitor Resistant : C3
PD-L1 expression	Hepatocellular Cancer	PD-L1 expression	Hepatocellular Cancer	PD1 inhibitor + Angiogenesis inhibitor Sensitive: C3 – Early Trials PD1 inhibitor + Angiogenesis inhibitor Sensitive : C3	PD1 inhibitor + Angiogenesis inhibitor Sensitive: C3 – Early Trials PD1 inhibitor + Angiogenesis inhibitor Sensitive : C3
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	Angiogenesis inhibitor Sensitive: C3 – Early Trials Angiogenesis inhibitor Sensitive : C3	Angiogenesis inhibitor Sensitive: C3 – Early Trials Angiogenesis inhibitor Sensitive : C3
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	Angiogenesis inhibitor Sensitive: C3 – Early Trials Angiogenesis inhibitor Sensitive : C3	Angiogenesis inhibitor Sensitive: C3 – Early Trials Angiogenesis inhibitor Sensitive : C3
EGFR mutation + TP53 mutation	Non Small Cell Lung Cancer	EGFR mutation + TP53 mutation	Non Small Cell Lung Cancer	EGFR inhibitor + Angiogenesis inhibitor Sensitive: C3 – Early Trials EGFR inhibitor + Angiogenesis inhibitor Sensitive : C3	EGFR inhibitor + Angiogenesis inhibitor Sensitive: C3 – Early Trials EGFR inhibitor + Angiogenesis inhibitor Sensitive : C3
PD-L1 overexpression	Non Small Cell Lung Cancer	PD-L1 overexpression	Non Small Cell Lung Cancer	Immunotherapy + Angiogenesis inhibitor Sensitive: C3 – Early Trials Immunotherapy + Angiogenesis inhibitor Sensitive : C3	Immunotherapy + Angiogenesis inhibitor Sensitive: C3 – Early Trials Immunotherapy + Angiogenesis inhibitor Sensitive : C3
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	PD1 inhibitor + Angiogenesis inhibitor Resistant: C3 – Early Trials PD1 inhibitor + Angiogenesis inhibitor Resistant : C3	PD1 inhibitor + Angiogenesis inhibitor Resistant: C3 – Early Trials PD1 inhibitor + Angiogenesis inhibitor Resistant : C3
PD-L1 expression	Lung Non-Small Cell Squamous Cancer	PD-L1 expression	Lung Non-Small Cell Squamous Cancer	Immunotherapy + Angiogenesis inhibitor Sensitive: C3 – Early Trials Immunotherapy + Angiogenesis inhibitor Sensitive : C3	Immunotherapy + Angiogenesis inhibitor Sensitive: C3 – Early Trials Immunotherapy + Angiogenesis inhibitor Sensitive : C3
PD-L1 expression	Lung Adenocarcinoma	PD-L1 expression	Lung Adenocarcinoma	Immunotherapy + Angiogenesis inhibitor Sensitive: C3 – Early Trials Immunotherapy + Angiogenesis inhibitor Sensitive : C3	Immunotherapy + Angiogenesis inhibitor Sensitive: C3 – Early Trials Immunotherapy + Angiogenesis inhibitor Sensitive : C3
HER-2 mutation	Non Small Cell Lung Cancer	HER-2 mutation	Non Small Cell Lung Cancer	Angiogenesis inhibitor Sensitive: C3 – Early Trials Angiogenesis inhibitor Sensitive : C3	Angiogenesis inhibitor Sensitive: C3 – Early Trials Angiogenesis inhibitor Sensitive : C3
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	Immunotherapy + Angiogenesis inhibitor Sensitive: C3 – Early Trials Immunotherapy + Angiogenesis inhibitor Sensitive : C3	Immunotherapy + Angiogenesis inhibitor Sensitive: C3 – Early Trials Immunotherapy + Angiogenesis inhibitor Sensitive : C3
EML4-ALK variant 3	Lung Adenocarcinoma	EML4-ALK variant 3	Lung Adenocarcinoma	Angiogenesis inhibitor Resistant: C4 – Case Studies Angiogenesis inhibitor Resistant : C4	Angiogenesis inhibitor Resistant: C4 – Case Studies Angiogenesis inhibitor Resistant : C4
TPM3-NTRK1 fusion	Colorectal Cancer	TPM3-NTRK1 fusion	Colorectal Cancer	E7050 Sensitive: D – Preclinical E7050 Sensitive : D	E7050 Sensitive: D – Preclinical E7050 Sensitive : D
BRAF mutation	Colorectal Cancer	BRAF mutation	Colorectal Cancer	SJ-C1044 Sensitive: D – Preclinical SJ-C1044 Sensitive : D	SJ-C1044 Sensitive: D – Preclinical SJ-C1044 Sensitive : D
KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	SJ-C1044 Sensitive: D – Preclinical SJ-C1044 Sensitive : D	SJ-C1044 Sensitive: D – Preclinical SJ-C1044 Sensitive : D

Angiogenesis inhibitor

Angiogenesis inhibitor

Associations(23)

Associations
(23)